http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 18 Aug 2026 09:19:42 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Benchmark+Reiterates+Speculative+Buy+Rating+on+Genelux+Corp.+%28GNLX%29/26941824.html <p>Benchmark analyst Bruce D. Jackson reiterated a Speculative Buy rating and $20.00 price target on Genelux Corp. (NASDAQ: GNLX).</p><p>The analyst commented, "Genelux continues to make progress on its clinical development program for Olvi-Vec (olvimulogene nanivacirepvec), a next-generation cancer immunotherapy using an oncolytic virus to treat aggressive and/or difficult-to-treat solid tumor types. Phase 1b/2 data published during 2Q showed that Olvi-Vec converts the tumor microenvironment from immunosuppressive (cold) to immunoreactive (hot) by inducing localized inflammation and a significant influx of CD8+ tumorinfiltrating lymphocytes (TILs), resensitizing the tumor to platinum-based chemotherapy. Management expects topline data from the Phase 3 OnPrime/GOG-3076 ovarian cancer http://www.streetinsider.com/Analyst+Comments/Benchmark+Reiterates+Speculative+Buy+Rating+on+Genelux+Corp.+%28GNLX%29/26941824.html Tue, 18 Aug 2026 09:19:42 -0400 GNLX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GENELUX+Corp++++++++++++++For%3A+Jun+30/26919428.html si-local-file:///var/storage/secattach/20260813/26919428.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GENELUX+Corp++++++++++++++For%3A+Jun+30/26919428.html Thu, 13 Aug 2026 13:06:00 -0400 GNLX O.02245151 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GENELUX+Corp++++++++++++++For%3A+Jun+30/26919428.html si-local-file:///var/storage/secattach/20260813/26919428.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++GENELUX+Corp++++++++++++++For%3A+Jun+30/26919428.html Thu, 13 Aug 2026 13:06:00 -0400 GNLX O.02245151 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Yu+Yong/26868565.html si-local-file:///var/storage/secattach/20260804/26868565.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Yu+Yong/26868565.html Tue, 04 Aug 2026 20:20:00 -0400 GNLX O.02245151 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Yu+Yong/26868565.html si-local-file:///var/storage/secattach/20260804/26868565.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Yu+Yong/26868565.html Tue, 04 Aug 2026 20:20:00 -0400 GNLX O.02245151 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Zindrick+Thomas/26868566.html si-local-file:///var/storage/secattach/20260804/26868566.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Zindrick+Thomas/26868566.html Tue, 04 Aug 2026 20:20:00 -0400 GNLX O.02245151 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Zindrick+Thomas/26868566.html si-local-file:///var/storage/secattach/20260804/26868566.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Zindrick+Thomas/26868566.html Tue, 04 Aug 2026 20:20:00 -0400 GNLX O.02245151 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Cappello+Joseph/26868567.html si-local-file:///var/storage/secattach/20260804/26868567.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Cappello+Joseph/26868567.html Tue, 04 Aug 2026 20:20:00 -0400 GNLX O.02245151 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Cappello+Joseph/26868567.html si-local-file:///var/storage/secattach/20260804/26868567.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GENELUX+Corp++++++++++++++For%3A+Aug+04++Filed+by%3A+Cappello+Joseph/26868567.html Tue, 04 Aug 2026 20:20:00 -0400 GNLX O.02245151 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html <p>Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company based in San Carlos, Calif., has appointed John W. Smither to its board of directors as an independent director and chair of the Audit Committee, according to a press release dated July 15, 2026.</p> <p>Smither currently serves as chief financial officer of MBX Biosciences (Nasdaq: MBX) and as a senior advisor to Frazier Life Sciences. He previously held chief financial officer or interim chief financial officer roles at several biotech companies, including Arcutis Biotherapeutics (Nasdaq: ARQT).</p> <p>Smither also serves on the board of directors of NewAmsterdam Pharma (Nasdaq: NAMS), where he chairs the Audit Committee, http://www.streetinsider.com/Board+Changes/Attovia+Therapeutics+names+John+Smither+to+board+of+directors/26771453.html Wed, 15 Jul 2026 08:30:31 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Press+Releases/Attovia+Therapeutics+Appoints+John+W.+Smither+to+Board+of+Directors/26771431.html <p align="left">SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee.</p> <p>“We are pleased to welcome John to our Board,” said Tao Fu, Founder and Chief Executive Officer of Attovia. “John is a proven leader in guiding biotechnology companies through critical stages of development. Having served as Chief Financial Officer across multiple public http://www.streetinsider.com/Press+Releases/Attovia+Therapeutics+Appoints+John+W.+Smither+to+Board+of+Directors/26771431.html Wed, 15 Jul 2026 08:30:00 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932 http://www.streetinsider.com/Press+Releases/Attovia+Therapeutics+Appoints+John+W.+Smither+to+Board+of+Directors/26771431.html <p align="left">SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the appointment of John W. Smither to its Board of Directors as an independent director and as Chair of the Audit Committee.</p> <p>“We are pleased to welcome John to our Board,” said Tao Fu, Founder and Chief Executive Officer of Attovia. “John is a proven leader in guiding biotechnology companies through critical stages of development. Having served as Chief Financial Officer across multiple public http://www.streetinsider.com/Press+Releases/Attovia+Therapeutics+Appoints+John+W.+Smither+to+Board+of+Directors/26771431.html Wed, 15 Jul 2026 08:30:00 -0400 A.34563541 A.50216981 A.50216999 ARQT GNLX MBX NAMS O.02245151 O.19939975 O.46864665 O.54602084 O.57742616 O.67271574 O.76617932